Clinical trials: Renal Tumors
Renal Pelvis Cancer
Radical Radiotherapy Versus Radical Surgery for UTUC
This study is a prospective cohort study, and the proposed plan is to recruit 30 patients with radical radiotherapy for renal pelvic ureteral cancer, according to the actual clinical situation, enrolling the same period of time…
- Trial name
- NCT06652009
- Testing
- Radical nephroureterectomy, Radical radiotherapy
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Peking University First Hospital
Carcinoma, Renal Cell
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC
This is a Phase I/II open-label, efficacy and safety study of bicalutamide in combination with sunitinib in patients with advanced renal cell carcinoma (RCC) who have been treated with a receptor tyrosine kinase inhibitor (RTKI)…
- Trial name
- NCT06222593
- Testing
- Bicalutamide in combination with Sunitinib
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- State University of New York at Buffalo
Carcinoma, Renal Cell, Prostatic Neoplasms
Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228
The purpose of this study is to evaluate the safety and tolerability of extended treatment with FK228 in patients with metastatic renal cell carcinoma or hormone refractory prostate cancer who have at least demonstrated stable…
- Trial name
- NCT00106301
- Testing
- FK228 (romidepsin)
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 2 people
- Sponsor
- Celgene
Breast Cancer, Lung Cancer
Pillars4Life Trial
This study aims to explore whether cancer patients can benefit from completing the Pillars4Life online coping program. This randomized control trial will have half its subject completing the program and the other half receiving…
- Conditions
- Breast Cancer, Lung Cancer, Esophageal Cancer, Colon Cancer
- Trial name
- Pillars4Life (NCT02465892)
- Testing
- Pillars4Life
- Where
- United States
- Volunteers
- 284 people
- Sponsor
- Duke University
Anterior Urethral Cancer, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
This study is about two chemotherapy study drug combinations (regimens) that are used for urothelial (bladder or upper urinary tract) cancer.
- Conditions
- Anterior Urethral Cancer, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Posterior Urethral Cancer, Recurrent Bladder Cancer
- Trial name
- NCT01639521
- Testing
- cisplatin, gemcitabine hydrochloride, methotrexate
- Sponsor
- University of Southern California
Unspecified Adult Solid Tumor, Protocol Specific
LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy drugs may have different effects in patients with different degrees of kidney function.
- Trial name
- NCT00003706
- Testing
- pemetrexed disodium
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology
A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
The purpose of this study is to evaluate the safety and pharmacokinetics and assess the immunogenicity and effectiveness of AGS-16C3F in subjects with renal cell cancer (RCC).
- Conditions
- Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology, Renal Cell Carcinoma With Clear Cell Histology, Renal Cell Carcinoma With Non-Clear Cell Histology
- Trial name
- NCT01672775
- Testing
- AGS-16C3F
- Where
- 9 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Agensys, Inc.
Renal Cell Carcinoma
Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma
This non-interventional study includes patients with advanced renal cell carcinoma who are treated with Sunitinib alone or combined with other systemic therapies.
- Trial name
- NCT01441661
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- Cancer Foundation, China
Cancer, Solid Tumor
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer.
- Trial name
- NCT00333502
- Testing
- Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- NewLink Genetics Corporation
Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
The main purpose of this study is to compare the objective response rate (ORR) and overall survival (OS) of bempegaldesleukin (NKTR-214: BEMPEG) combined with nivolumab to that of tyrosine kinase inhibitor (TKI) monotherapy…
- Trial name
- NCT03729245
- Testing
- bempegaldesleukin, sunitinib, nivolumab
- Where
- 96 sites in United States, Argentina and 8 more
- Volunteers
- 623 people
- Sponsor
- Nektar Therapeutics
Renal Cell Carcinoma Stage I
An Exploratory Study on the Failure of Immunotherapy With Vorolanib Combined With Everolimus
This single-arm exploratory study included patients with renal clear cell carcinoma who had previously received one type of immunotherapy and failed. The specific regimen was Vorolanib 200mg PO.QD combined with everolimus 5mg QD.
- Trial name
- NCT06730672
- Testing
- Vorolanib combined with Everolimus Formation
- Where
- 2 sites in China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic urinary tumors and other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum…
- Trial name
- NCT05393427
- Testing
- BL-B01D1
- Where
- 4 sites in China
- Volunteers
- 4 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Carcinoma, Renal Cell, Kidney Diseases
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining varlilumab and atezolizumab.
- Conditions
- Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urogenital Neoplasms
- Trial name
- NCT02543645
- Testing
- Combination of Varlilumab and Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Celldex Therapeutics
Kidney Cancer
ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of kidney cancer.
- Trial name
- NCT00014183
- Testing
- gefitinib
- Where
- 2 sites in United States
- Sponsor
- University of Maryland, Baltimore
Wilms Tumor
Study of Wilms Tumors Among Patients of Shefa Al-Orman Children Cancer Hospital
The goal of this cross sectional observational study is to determine the percentage of Wilms tumors among pediatric cancers at Shefa Al-Orman Children Cancer Hospital from june 2020 to june 2024,to study the outcome of patients…
- Trial name
- NCT06288802
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- South Egypt Cancer Institute
cT2a N0NxM0 Renal Tumor
Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)
Axitinib (AXITINIB) is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 which has achieved objective response rate of 44.2% in phase II study in cytokine-refractory metastatic…
- Trial name
- AXIPAN (NCT02597322)
- Testing
- AXITINIB
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Renal Cell Carcinoma
Yorkshire Kidney Screening Trial
Kidney cancer is the 8th most common cancer in Yorkshire. It has a poor survival rate, with only 6 out of 10 patients diagnosed with kidney cancer still alive after 5 years.
- Trial name
- YKST (NCT05005195)
- Testing
- Low dose abdominal computed tomography scan
- Where
- United Kingdom
- Volunteers
- 5,850 people, healthy volunteers welcome
- Sponsor
- University of Leeds
Carcinoma, Renal Cell
Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer
The purpose of this study is to determine if the combination of therapy to strengthen the immune system (Interleukin - 2) plus a specific tumor target therapy (Bevacizumab) can prolong the time between the start of treatment and…
- Trial name
- NCT00440973
- Testing
- Bevacizumab, Interleukin-2
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- The Methodist Hospital Research Institute
Kidney Cancer, Leukemia
Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation
RATIONALE: Traumeel® S (a mouth rinse) may be effective in preventing or decreasing the severity of oral mucositis caused by chemotherapy in young patients who are undergoing stem cell transplantation.
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00080873
- Testing
- Traumeel S
- Where
- 44 sites in United States, Australia and 2 more
- Volunteers
- 195 people
- Sponsor
- Children's Oncology Group
Fatigue, Recurrent Renal Cell Cancer
Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer
The purpose of this research study is to determine how sunitinib (sunitinib malate) causes fatigue. Patients will be asked to complete a brief questionnaire (survey) to rate their levels of fatigue every two weeks while they are…
- Conditions
- Fatigue, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT01740154
- Testing
- transcranial magnetic stimulation, electromyography, survey administration
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Case Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.